CERVIX CANCER COMMITTEE AGENDA
WEDNESDAY, MAY 30, 2018, 3:00PM – 4:30PM
CHAIR: BRAD MONK     CO-CHAIR: ANTONIO CASADO
EXHIBIT HALL, PALMER HOUSE HILTON HOTEL, CHICAGO
HARMONIZATION LIAISONS: STONEBRAKER/KELLER (OPS), REUSS (STATS)
Please sign Attendance Forms

WELCOME & INTRODUCTIONS

COI DECLARATIONS

APPROVAL OF MINUTES/REPORT: NOVEMBER 2017 (POSTED ON GCIG WEBSITE)

MOTION: ________________________________ SECONDED: ________________________________

CLOSED/PUBLISHED TRIALS:

- Impact of Tumour Histology on survival in advanced cervical carcinoma:
  an NRG Oncology/Gynaecologic Oncology Group Study
  Br J Cancer. 2018 Jan; 118(2):162-170

ON-GOING CLINICAL TRIALS:

a) ANZGOG
   OUTBACK
   EXCISE

b) BGOG
   ENGOT-cx1 RANDOMIZED PHASE II OF PACLITAXEL-CARBOPLATIN +/- NINTEDANIB

   VERGOTE

c) CCTG
   CONTESSA / NEOCON-F
   SHAPE

   PLANTE

   PLANTE

d) DGOG
   GROINSS-VII
   GROINSS-VIII

   CREUTZBERG

   CREUTZBERG

e) GINECO
   SENTICOL III

   LECURU

f) NRG/GOG-F
   NRG 278
   GOG 3009
   NRG GY006
   NRG 279
   GOG 3016
   RTOG 0724

   MONK

   MONK

   MONK

   MONK

   MONK

   MONK

g) KGOG
   GOG 263
   TACO

   RYU

   RYU

h) NCRI
   INTERLACE

   MCCORMACK
**Update of Trials in Development:**
- Excisional treatment in women with cervical adenocarcinoma-in-situ (AIS): Cohen
  A prospective randomised controlled non-inferiority trial to compare AIS recurrence after loop electrosurgical excision procedure (LEEP) to cold knife cone biopsy (CKC)

**New Concepts/Proposals:**
- AGOG: A Phase 2 Trial of Pembrolizumab combined with chemoradiation Lai
  in patients with $^{18}$F-FDG PET/CT-defined poor-prognostic cervical cancer

**Discussion/Future Directions:**

**Adjourn**